SureTrader
Home > Boards > US Listed > Biotechs >

Aurinia Pharmaceuticals Inc (AUPH)

AUPH RSS Feed
Add AUPH Price Alert      Hide Sticky   Hide Intro
Moderator: Jesspro
Search This Board: 
Last Post: 4/22/2018 1:36:03 PM - Followers: 159 - Board type: Free - Posts Today: 8

Aurinia is a late-stage biopharmaceutical company providing novel products specifically engineered to treat a limited, targeted patient population suffering from serious disease states for which there is a high unmet medical need.

*Aurinia Pharmaceuticals Inc.
http://www.auriniapharma.com/
 

Pipeline

 

Pipeline

Pipeline

Candidate & Indication Development Stage
Preclinical Phase 1 Phase 2 Phase 3 Market
VOCLOSPORINLupus Nephritis (LN)
Preclinical Phase complete
Phase 1 Phase complete
Phase 2 Phase in progress
Phase 3 Phase not started
Market Phase not started

Aurinia is committed to working in areas of high unmet medical need and is poised to deliver the first approved therapy in the U.S. and Europe for the treatment of lupus nephritis, or LN.

The Voclosporin Advantage

Voclosporin, an investigational drug, is a novel and potentially best-in-class calcineurin inhibitor (“CNI”) with clinical data in over 2,000 patients across indications. Voclosporin is an immunosuppressant, with a synergistic and dual mechanism of action that has the potential to improve near- and long-term outcomes in lupus nephritis (LN) when added to standard of care mycophenolate mofetil (MMF). It has been granted “fast track status” by the U.S. Food & Drug Administration (FDA).

Voclosporin Could Transform the LN treatment Landscape

Voclosporin has the potential to become a best in class medication and the first approved treatment for LN in the U.S. and Europe, effectively altering the current treatment paradigm for the disease.

Advantages of Voclosporin Combined with Standard of Care (SoC)

Our clinical data suggests that adding voclosporin to the current SoC of MMF for the treatment of lupus nephritis (LN) will yield superior results to using the standard of care alone.

Additionally, voclosporin may prove to be an ideal therapy for lupus nephritis due to advantages such as:

  • Improved efficacy
    Increased safety
    Oral administration
    Improved average time to renal response or remission
    Improved duration of renal response
    Reduction in steroid burden
    Potential first line add-on to MMF
    Fewer toxic immunosuppressants required
Benefits of Voclosporin

Potential Benefits of Voclosporin

In clinical trials, Voclosporin has been shown to be especially effective in the presence of low dose steroids with rapid reduction of LN inflammatory markers and overall improved renal stability.

The list of potential product benefits includes:

LN Critical Need Voclosporin (based on AURA Results)
Control of Active Disease
Rapid Disease Control
Lower Steroid Burden
Impact on Extra-renal disease
Convenient Treatment Regimen

In previous studies, over 2000 patients have been treated with Voclosporin with no abnormal or unexpected SAE’s

Well Characterized Safety Profile

Efficacy of calcineurin inhibition has already been established. Voclosporin has a well-characterized safety profile (over 2,000 patient exposures across multiple years) across indications.

No new safety signals were observed with the use of Voclosporin in LN patients; Voclosporin was well-tolerated and renal function remained stable in clinical studies. The overall safety profile is consistent with other immunosuppressive drugs.

 

SureTrader
AUPH
Current Price
Volume:
Bid Ask Day's Range
  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
SureTrader
PlusOneCoin Top Posts
No plusone'd posts yet. Be the first!
PostSubject
#6986   Read the site! Make sure! Hotrodder1 04/22/18 01:36:03 PM
#6985   Just to clarify it’s any shares purchased between Maciste 04/22/18 01:35:17 PM
#6984   The claims administrator. Www.AriadSecuritiesLitigation.com Hotrodder1 04/22/18 01:33:40 PM
#6983   BY the way we’re you notified by someone Maciste 04/22/18 01:11:24 PM
#6982   Thanks for the info. I need to Maciste 04/22/18 01:05:50 PM
#6981   Owners of Ariad that bought between 12/11/12 and Hotrodder1 04/22/18 12:57:18 PM
#6980   What are you talking about? Maciste 04/22/18 12:45:10 PM
#6979   I just finish filling out paperwork on the Hotrodder1 04/22/18 11:34:50 AM
#6978   What's up with this Indian Company offering Voclosporin? moosedogger 04/21/18 02:39:32 PM
#6977   "...explosive component to the manufacturing process..." moosedogger 04/20/18 04:12:00 PM
#6976   There's an explosive component to the manufacturing process, Lunacy aka John Galt 04/20/18 02:56:34 PM
#6975   Thanks Luna- I may have assumed "difficult" also moosedogger 04/20/18 02:53:52 PM
#6974   I don't know the manufacturing cost, or that Lunacy aka John Galt 04/20/18 02:27:24 PM
#6973   Luna, re "...price tag closer to $50k than $35k." moosedogger 04/20/18 01:57:01 PM
#6972   Well stated Moose.. unfortunately the number of patients biotech_researcher 04/20/18 12:43:56 PM
#6971   My guess is that we see a price Lunacy aka John Galt 04/20/18 12:20:32 PM
#6970   ALLINforLupusNephritis.com, says 200K have LN in USA moosedogger 04/20/18 11:53:40 AM
#6968   No one truly knows how many have SLE moosedogger 04/20/18 10:45:57 AM
#6967   Who cares what is at the bottom? The biotech_researcher 04/20/18 10:19:24 AM
#6966   “BR, I’m waiting for your answer about the biotech_researcher 04/20/18 10:16:40 AM
#6965   "....they claim 278 million individuals have SLE." moosedogger 04/20/18 09:46:59 AM
#6964   Been saying the same thing to myself. Notice short LivingTheDream 04/20/18 08:18:08 AM
#6963   Re Cantor report- I like the fact that moosedogger 04/20/18 08:09:41 AM
#6962   BR, I’m waiting for your answer about the Jesspro 04/20/18 07:47:09 AM
#6961   Doesn’t the legend at the bottom indicate an Jesspro 04/19/18 10:59:43 PM
#6960   Jess, read the table in the Cantor document. biotech_researcher 04/19/18 10:50:56 PM
#6959   I agree that Cantor is complete junk reasearch. SvsB 04/19/18 10:45:23 PM
#6958   BR, can you post the link where they Jesspro 04/19/18 10:41:34 PM
#6957   I’ve some other reports like that from Cantor. Junk. biotech_researcher 04/19/18 06:58:44 PM
#6956   Cantor is screwy with some of their data: Investment biotech_researcher 04/19/18 06:57:30 PM
#6955   Here's how Cantor gets their $16 AUPH target: moosedogger 04/19/18 05:11:14 PM
#6954   I took it out for you to make Jesspro 04/18/18 10:40:15 PM
#6953   Hey Jess, Lunacy aka John Galt 04/18/18 06:42:54 PM
#6952   You're hearing "Let it ride" but can't you moosedogger 04/18/18 12:19:30 PM
#6951   I bought more today, and now better step biotech_researcher 04/18/18 11:55:41 AM
#6950   Bingo Moose! Aurinia wants to insure approval of biotech_researcher 04/18/18 11:53:25 AM
#6949   Or maybe the SLE carrot is a shrewd moosedogger 04/18/18 11:45:12 AM
#6948   "The SLEDAI score calculator consists of a list moosedogger 04/18/18 11:22:29 AM
#6947   Moose, is SLEDAI scoring being used in both Jesspro 04/18/18 10:50:23 AM
#6946   Immuphara is for SLE; Aurinia is for LN. biotech_researcher 04/18/18 10:02:49 AM
#6945   It’s all in the game. Auph is on Jesspro 04/18/18 09:58:31 AM
#6944   It's a puzzlement, definitely. Hard to believe that moosedogger 04/18/18 09:33:26 AM
#6943   They want to recoup some of the costs Jesspro 04/18/18 09:19:42 AM
#6942   ImmuPharma not giving up on Lupuzor moosedogger 04/18/18 08:26:58 AM
#6941   Thanks Jess- good to hear. Looking forward moosedogger 04/17/18 11:59:12 AM
#6939   I did feel this was the likely outcome, Lunacy aka John Galt 04/17/18 10:58:30 AM
#6938   Thanks Jess- much appreciated. You are correct moosedogger 04/17/18 09:12:34 AM
#6937   Good post Moose. You and Luna make up Jesspro 04/17/18 09:00:37 AM
#6936   Thanks. I give Luna A+++ and myself a moosedogger 04/17/18 08:35:32 AM
#6935   Luna and Moose, thank you both for you biotech_researcher 04/17/18 08:22:34 AM
PostSubject